CORT logo

CORT
Corcept Therapeutics Inc

4,507
Mkt Cap
$4B
Volume
1.96M
52W High
$114.71
52W Low
$28.66
PE Ratio
46.60
CORT Fundamentals
Price
$38.12
Prev Close
$37.60
Open
$37.81
50D MA
$37.49
Beta
1.31
Avg. Volume
1.98M
EPS (Annual)
$0.8182
P/B
6.24
Rev/Employee
$1.04M
$3,809.50
Loading...
Loading...
News
all
press releases
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss CORT INVESTOR ALERT: Hagens Berman...
PR Newswire·5h ago
News Placeholder
More News
News Placeholder
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated...
PR Newswire·17h ago
News Placeholder
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT Corcept Therapeutics Incorporated Sued for Securities Law Violations...
PR Newswire·17h ago
News Placeholder
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...
Business Wire·2d ago
News Placeholder
Joseph Belanoff Sells 26,198 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) CEO Joseph Belanoff sold 26,198 shares of the firm's stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief...
MarketBeat·3d ago
News Placeholder
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
Key PointsIt earned FDA approval for its cancer drug, Lifyorli...
Nasdaq News: Markets·3d ago
News Placeholder
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·3d ago
News Placeholder
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat reports...
MarketBeat·4d ago
News Placeholder
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit...
PR Newswire·4d ago
News Placeholder
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
Zacks·4d ago
<
1
2
...
>

Latest CORT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.